Masimo (MASI) Proxy Filing summary

Executive summary

• Board unanimously approved an agreement to be acquired by Danaher for $180 per share, with the transaction expected to close in the second half of 2026.

• Masimo will operate as a standalone business unit within Danaher's Diagnostics segment, retaining its brand, headquarters, and core values.

• The acquisition aims to accelerate innovation and growth, leveraging Danaher's resources and alignment with Masimo's mission.

• Transaction closing is subject to customary conditions, including regulatory and shareholder approvals.

• Forward-looking statements highlight potential risks, including regulatory approvals, competing offers, and integration challenges.

Voting matters and shareholder proposals

• Shareholders will receive a proxy statement and vote on the proposed acquisition at a forthcoming meeting.

• Proxy materials will be filed with the SEC and mailed to stockholders in advance of the meeting.

Board of directors and corporate governance

• Board of Directors unanimously approved the acquisition agreement.

• Information about directors and executive officers is available in recent proxy statements and SEC filings.